Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

FGEN

FibroGen

NASDAQ

Real-time Quotes | Nasdaq Last Sale

38.07

-12.46

-24.66%

Pre Market: 38.00 -0.07 -0.18% 04:44 03/03 EST

OPEN

38.00

PREV CLOSE

50.53

HIGH

39.42

LOW

33.84

VOLUME

133

TURNOVER

52 WEEK HIGH

57.21

52 WEEK LOW

22.65

MARKET CAP

3.46B

P/E (TTM)

-14.5183

News

Financial

Releases

Corp Actions

Analysis

Profile

Mid-Afternoon Market Update: Crude Oil Down 1.5%; Communication Systems Shares Spike Higher

Toward the end of trading Tuesday, the Dow traded up 0.08% to 31,562.10 while the NASDAQ fell 0.87% to 13,470.33. The S&P also fell, dropping 0.14% to 3,896.45.

Benzinga · 13h ago

DDD, NVAX, LMND and RKT among midday movers

Gainers: NanoViricides, Inc. (NNVC) +89%.Communications Systems, Inc. (JCS) +74%.Amyris, Inc. (AMRS) +41%.Hovnanian Enterprises, Inc. (HOV) +37%.Rocket Companies, Inc. (RKT) +36%.Perion Network Ltd. (PERI) +27%.The OLB Group, Inc. (OLB) +25%.Novan, Inc.

Seekingalpha · 15h ago

Mid-Day Market Update: Nasdaq Down 100 Points; NanoViricides Shares Spike Higher

Midway through trading Tuesday, the Dow traded down 0.18% to 31,478.24 while the NASDAQ fell 0.77% to 13,483.57. The S&P also fell, dropping 0.40% to 3,886.37.

Benzinga · 16h ago

FibroGen Stock Collapses After Its Latest-Stage Drug Faces Another Delay

FibroGen suffered a setback after U.S. regulators requested an additional meeting before reviewing the company's anemia treatment. In response, FGEN stock crashed on Tuesday.

Investor's Business Daily · 17h ago

NanoViricides, CHF Solutions leads healthcare gainers; FibroGen, Neuronetics among major losers

Gainers: NanoViricides NNVC +63%, CHF Solutions CHFS +25%, Avenue Therapeutics (ATXI) +19%, Fortress Biotech FBIO +17%, STRATA Skin Sciences (SSKN) +15%.Losers: FibroGen FGEN -30%, Neuronetics STIM -14%, RedHill Biopharma RDHL -13%, Morphic Holding (MORF) ...

Seekingalpha · 17h ago

DJ FibroGen Down Nearly 31%, On Pace for Record Percent Decrease -- Data Talk

Dow Jones · 18h ago

Mid-Morning Market Update: Markets Mostly Lower; Target Profit Tops Views

Following the market opening Tuesday, the Dow traded up 0.04% to 31,549.29 while the NASDAQ fell 0.52% to 13,518.42. The S&P also fell, dropping 0.20% to 3,894.08.

Benzinga · 18h ago

FibroGen shares plummet 24% as FDA meeting, Jefferies downgrade weigh

Jefferies analyst Michael Yee has downgraded shares of FibroGen, Inc. (FGEN) to hold from buy.He also lower his price target to $45 from $75.Yee says that yesterday's announcement that the

Seekingalpha · 19h ago

Forecast

EPSBVPSCFPS

Actual (USD)

Estimate (USD)

Income StatementMore

Net IncomeTotal RevenueOperating Income

Net Income (USD)

YoY (%)

Balance SheetMore

Total Assets (USD)

Total Liabilities (USD)

Debt to Asset (%)

Cash FlowMore

OperatingInvestingFinancing

Operating (USD)

YoY (%)

Learn about the latest financial forecast of FGEN. Analyze the recent business situations of FibroGen through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average FGEN stock price target is 62.33 with a high estimate of 91.00 and a low estimate of 44.00.

EPS

Institutional Holdings

Institutions: 343

Institutional Holdings: 75.54M

% Owned: 83.00%

Shares Outstanding: 91.01M

TypeInstitutionsShares

Increased

5.70M

New

500.65K

Decreased

3.12M

Sold Out

Performance
Asset Allocation
Dividend History

No Data

Industry

Biotechnology & Medical Research

-2.03%

Pharmaceuticals & Medical Research

-0.88%

Key Executives

Chairman/Director

James Schoeneck

Chief Executive Officer/Director

Enrique Conterno

Chief Financial Officer

Pat Cotroneo

Other

K. Peony Yu

Senior Vice President

Christine Chung

Senior Vice President

Elias Kouchakji

Other

Percy Carter

Other

Mark Eisner

Other

Thane Wettig

Lead Director/Independent Director

Thomas Kearns

Director

Aoife Brennan

Director

Benjamin Cravatt

Independent Director

Suzanne Blaug

Independent Director

Jeffrey Edwards

Independent Director

Jeffrey Henderson

Independent Director

Maykin Ho

Independent Director

Kalevi Kurkijarvi

Independent Director

Gerald Lema

Independent Director

Rory Riggs

Independent Director

Toshinari Tamura

Dividends
Splits
Insider Activity

No Data

All
Financials
Insiders

About FGEN

FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19).

Webull offers kinds of FibroGen Inc stock information, including NASDAQ:FGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FGEN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FGEN stock methods without spending real money on the virtual paper trading platform.